Lipid metabolism enzymes and transcription factors

Lipid metabolism enzymes and transcription factors encompass a broad array of proteins that orchestrate the biochemical pathways of lipid synthesis, degradation, and transport. This group includes rate-limiting enzymes like HMG-CoA reductase, which governs cholesterol production, and nuclear transcription factors such as Peroxisome Proliferator-Activated Receptors (PPARs) and Sterol Regulatory Element-Binding Proteins (SREBPs) that regulate the expression of genes involved in fatty acid and glucose metabolism (Source: NIH, UniProt). These molecules are critical for maintaining cellular and systemic energy balance, and their dysfunction is a primary driver of metabolic diseases such as dyslipidemia, type 2 diabetes, and non-alcoholic fatty liver disease (Source: PubMed, StatPearls). Pharmacological agents targeting these proteins, including statins, fibrates, and thiazolidinediones, are widely used to manage cardiovascular risk and metabolic health by modulating lipid levels and insulin sensitivity (Source: PubChem). Because this term describes a functional class rather than a specific protein, it serves as an umbrella category for numerous distinct therapeutic targets.

Other names

Lipid metabolic regulatorsLipid metabolism proteinsLipid metabolic pathway components

Mechanisms include the competitive inhibition of biosynthetic enzymes (e.g., HMG-CoA reductase), the agonism of nuclear receptors (e.g., PPARs) to upregulate lipid-clearing genes, and the inhibition of proteins involved in lipid absorption and recycling (e.g., NPC1L1 or PCSK9) (Source: PubMed).